

Friedrich Scheiflinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11263735/publications.pdf>

Version: 2024-02-01

31
papers

3,626
citations

236925

25
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

2350
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. <i>Blood</i> , 2005, 106, 1932-1937.	1.4	288
2	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. <i>Blood</i> , 2005, 106, 1262-1267.	1.4	275
3	Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. <i>Blood</i> , 2007, 109, 2815-2822.	1.4	248
4	von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. <i>Blood</i> , 2009, 114, 3329-3334.	1.4	228
5	Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. <i>Blood</i> , 2003, 102, 3241-3243.	1.4	225
6	Systemic antithrombotic effects of ADAMTS13. <i>Journal of Experimental Medicine</i> , 2006, 203, 767-776.	8.5	222
7	Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). <i>Blood</i> , 2002, 100, 3626-3632.	1.4	216
8	Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. <i>Blood</i> , 2004, 103, 4514-4519.	1.4	204
9	ADAMTS13: a new link between thrombosis and inflammation. <i>Journal of Experimental Medicine</i> , 2008, 205, 2065-2074.	8.5	190
10	Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. <i>Blood</i> , 2013, 121, 1039-1048.	1.4	155
11	Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. <i>Blood</i> , 2005, 105, 542-544.	1.4	152
12	ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice. <i>Blood</i> , 2016, 127, 2337-2345.	1.4	138
13	Complement Factor H Mutation in Familial Thrombotic Thrombocytopenic Purpura with ADAMTS13 Deficiency and Renal Involvement. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1177-1183.	6.1	129
14	A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. <i>Blood</i> , 2012, 119, 6128-6135.	1.4	109
15	Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. <i>Blood</i> , 2012, 120, 5217-5223.	1.4	107
16	Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. <i>Blood</i> , 2015, 125, 1180-1188.	1.4	102
17	Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. <i>Blood</i> , 2006, 107, 118-125.	1.4	99
18	ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. <i>British Journal of Haematology</i> , 2003, 120, 821-824.	2.5	89

#	ARTICLE	IF	CITATIONS
19	Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). <i>Thrombosis and Haemostasis</i> , 2006, 95, 212-220.	3.4	86
20	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. <i>Thrombosis and Haemostasis</i> , 2006, 96, 454-464.	3.4	72
21	Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2336-2342.	2.4	64
22	Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. <i>Blood</i> , 2005, 106, 925-928.	1.4	57
23	Expression and characterization of recombinant human ADAMTS-13. <i>Seminars in Hematology</i> , 2004, 41, 24-33.	3.4	53
24	Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. <i>Haematologica</i> , 2014, 99, 779-787.	3.5	51
25	Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura. <i>Haematologica</i> , 2014, 99, e58-e60.	3.5	32
26	Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 156-158.	3.8	20
27	A patient with SLE-associated thrombotic microangiopathy and non-neutralizing antibodies against ADAMTS13. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1720-1722.	0.7	8
28	Identification of cysteine thiolâ€¢based linkages in ADAMTS13 in support of a nonâ€¢proteolytic regulation of von Willebrand factor. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2099-2109.	3.8	5
29	Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey. <i>Blood Coagulation and Fibrinolysis</i> , 2022, 33, 56-60.	1.0	2
30	ADAMTS13: von Willebrand Factor-Cleaving Protease. , 2013, , 1199-1206.		0
31	Potential Clinical Use of Recombinant Human ADAMTS13. , 2015, , 159-184.		0